Research programme: lung disorders therapy - Emergent BioDefense Operations Lansing/University of Maryland
Alternative Names: Research programme: mucin release inhibitors - Emergent BioDefense Operations Lansing/University of Maryland; Research programme: polycationic peptides - Emergent BioDefense Operations Lansing/University of MarylandLatest Information Update: 01 May 2007
At a glance
- Originator University of Maryland, Baltimore
- Developer Emergent BioDefense Operations Lansing; University of Maryland, Baltimore
- Class
- Mechanism of Action Mucin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Bronchiectasis; Bronchitis; Cystic fibrosis
Most Recent Events
- 16 Jun 2003 The assets of Antex Biologics and Antex Pharma have been acquired by BioPort Corporation
- 14 Nov 2002 This programme is still in active development
- 06 Oct 2000 Preclinical development for Asthma in USA (Unknown route)